Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
Lung cancer remains the leading cause of cancer-related death with an incidence that continues to increase in both sexes and all ages. However, 80% to 90% of lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% are small cell lung cancer. Adenocarcinoma is the most common...
Main Authors: | Nathalie Baudoux, Alex Friedlaender, Alfredo Addeo |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-02-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.1177/11795549231152948 |
Similar Items
-
Management of stage III non-small-cell lung cancer: rays of hope
by: Floryane Kim, et al.
Published: (2024-02-01) -
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
by: Kirstin Perdrizet, et al.
Published: (2021-12-01) -
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01) -
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
by: Alfredo Addeo
Published: (2022-06-01) -
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
by: Maxime Borgeaud, et al.
Published: (2023-02-01)